Literature DB >> 20054868

Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity.

Rinke Stienstra1, Fredy Saudale, Caroline Duval, Shohreh Keshtkar, Johanna E M Groener, Nico van Rooijen, Bart Staels, Sander Kersten, Michael Müller.   

Abstract

UNLABELLED: Kupffer cells have been implicated in the pathogenesis of various liver diseases. However, their involvement in metabolic disorders of the liver, including fatty liver disease, remains unclear. The present study sought to determine the impact of Kupffer cells on hepatic triglyceride storage and to explore the possible mechanisms involved. To that end, C57Bl/6 mice rendered obese and steatotic by chronic high-fat feeding were treated for 1 week with clodronate liposomes, which cause depletion of Kupffer cells. Loss of expression of marker genes Cd68, F4/80, and Clec4f, and loss of Cd68 immunostaining verified almost complete removal of Kupffer cells from the liver. Also, expression of complement components C1, the chemokine (C-C motif) ligand 6 (Ccl6), and cytokines interleukin-15 (IL-15) and IL-1beta were markedly reduced. Importantly, Kupffer cell depletion significantly decreased liver triglyceride and glucosylceramide levels concurrent with increased expression of genes involved in fatty acid oxidation including peroxisome proliferator-activated receptor alpha (PPARalpha), carnitine palmitoyltransferase 1A (Cpt1alpha), and fatty acid transport protein 2 (Fatp2). Treatment of mice with IL-1beta decreased expression of PPARalpha and its target genes, which was confirmed in primary hepatocytes. Consistent with these data, IL-1beta suppressed human and mouse PPARalpha promoter activity. Suppression of PPARalpha promoter activity was recapitulated by overexpression of nuclear factor kappaB (NF-kappaB) subunit p50 and p65, and was abolished upon deletion of putative NF-kappaB binding sites. Finally, IL-1beta and NF-kappaB interfered with the ability of PPARalpha to activate gene transcription.
CONCLUSION: Our data point toward important cross-talk between Kupffer cells and hepatocytes in the regulation of hepatic triglyceride storage. The effect of Kupffer cells on liver triglycerides are at least partially mediated by IL-1beta, which suppresses PPARalpha expression and activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20054868     DOI: 10.1002/hep.23337

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  157 in total

Review 1.  Mechanisms of inflammatory responses in obese adipose tissue.

Authors:  Shengyi Sun; Yewei Ji; Sander Kersten; Ling Qi
Journal:  Annu Rev Nutr       Date:  2012-03-09       Impact factor: 11.848

2.  Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells.

Authors:  Chad N Brocker; Jiang Yue; Donghwan Kim; Aijuan Qu; Jessica A Bonzo; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-01-12       Impact factor: 4.052

3.  NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid.

Authors:  Can Cai; Xiwen Zhu; Peizhi Li; Jinzheng Li; Jianping Gong; Wei Shen; Kun He
Journal:  Inflammation       Date:  2017-12       Impact factor: 4.092

4.  Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.

Authors:  Magar Ghazarian; Xavier S Revelo; Mark K Nøhr; Helen Luck; Kejing Zeng; Helena Lei; Sue Tsai; Stephanie A Schroer; Yoo Jin Park; Melissa Hui Yen Chng; Lei Shen; June Ann D'Angelo; Peter Horton; William C Chapman; Diane Brockmeier; Minna Woo; Edgar G Engleman; Oyedele Adeyi; Naoto Hirano; Tianru Jin; Adam J Gehring; Shawn Winer; Daniel A Winer
Journal:  Sci Immunol       Date:  2017-04-21

5.  Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.

Authors:  Thomas Klein; Masato Fujii; Jan Sandel; Yuichiro Shibazaki; Kyoko Wakamatsu; Michael Mark; Hiroyuki Yoneyama
Journal:  Med Mol Morphol       Date:  2013-09-19       Impact factor: 2.309

6.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

7.  Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice.

Authors:  Ganesan Murali; Ginger L Milne; Corey D Webb; Ann B Stewart; Ryan P McMillan; Brandon C Lyle; Matthew W Hulver; Viswanathan Saraswathi
Journal:  J Lipid Res       Date:  2012-07-29       Impact factor: 5.922

Review 8.  Role of macrophages and monocytes in hepatitis C virus infections.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 9.  Alcohol Modulation of the Postburn Hepatic Response.

Authors:  Michael M Chen; Stewart R Carter; Brenda J Curtis; Eileen B O'Halloran; Richard L Gamelli; Elizabeth J Kovacs
Journal:  J Burn Care Res       Date:  2017 Jan/Feb       Impact factor: 1.845

10.  Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.

Authors:  Annie-Carole Tosello-Trampont; Susan G Landes; Virginia Nguyen; Tatiana I Novobrantseva; Young S Hahn
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.